301 related articles for article (PubMed ID: 19686597)
1. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.
van der Heijde DM; Revicki DA; Gooch KL; Wong RL; Kupper H; Harnam N; Thompson C; Sieper J;
Arthritis Res Ther; 2009; 11(4):R124. PubMed ID: 19686597
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
van der Heijde D; Breban M; Halter D; DiVittorio G; Bratt J; Cantini F; Kary S; Pangan AL; Kupper H; Rathmann SS; Sieper J; Mease PJ
Rheumatology (Oxford); 2015 Jul; 54(7):1210-9. PubMed ID: 25541333
[TBL] [Abstract][Full Text] [Related]
4. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
Deodhar AA; Dougados M; Baeten DL; Cheng-Chung Wei J; Geusens P; Readie A; Richards HB; Martin R; Porter B
Arthritis Rheumatol; 2016 Dec; 68(12):2901-2910. PubMed ID: 27390130
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
Revicki DA; Luo MP; Wordsworth P; Wong RL; Chen N; Davis JC;
J Rheumatol; 2008 Jul; 35(7):1346-53. PubMed ID: 18484692
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.
van der Heijde D; Schiff MH; Sieper J; Kivitz AJ; Wong RL; Kupper H; Dijkmans BA; Mease PJ; Davis JC;
Ann Rheum Dis; 2009 Jun; 68(6):922-9. PubMed ID: 18701556
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
8. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.
Maksymowych WP; Gooch KL; Wong RL; Kupper H; van der Heijde D
J Rheumatol; 2010 Feb; 37(2):385-92. PubMed ID: 19955052
[TBL] [Abstract][Full Text] [Related]
9. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis.
Reilly MC; Gooch KL; Wong RL; Kupper H; van der Heijde D
Rheumatology (Oxford); 2010 Apr; 49(4):812-9. PubMed ID: 20100797
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement.
Horneff G; Fitter S; Foeldvari I; Minden K; Kuemmerle-Deschner J; Tzaribacev N; Thon A; Borte M; Ganser G; Trauzeddel R; Huppertz HI
Arthritis Res Ther; 2012 Oct; 14(5):R230. PubMed ID: 23095307
[TBL] [Abstract][Full Text] [Related]
11. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.
Reveille JD; Deodhar A; Ince A; Chan EKH; Peterson S; Li N; Hsia EC; Kim L; Lo KH; Xu S; Harrison DD; Han C
Value Health; 2020 Oct; 23(10):1281-1285. PubMed ID: 33032770
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis.
Hu Z; Xu M; Li Q; Lin Z; Liao Z; Cao S; Wei Q; Zhang YL; Li T; Jin O; Huang J; Pan Y; Wu Y; Deng X; Gu J
Int J Rheum Dis; 2012 Aug; 15(4):358-65. PubMed ID: 22898215
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635
[TBL] [Abstract][Full Text] [Related]
14. Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis.
Kimel M; Revicki D; Rao S; Fryback D; Feeny D; Harnam N; Thompson C; Cifaldi M
Clin Exp Rheumatol; 2011; 29(4):624-32. PubMed ID: 21813060
[TBL] [Abstract][Full Text] [Related]
15. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
van der Heijde D; Deodhar A; Braun J; Mack M; Hsu B; Gathany TA; Inman RD; Han C;
J Rheumatol; 2014 Jun; 41(6):1095-103. PubMed ID: 24737912
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
Lambert RG; Salonen D; Rahman P; Inman RD; Wong RL; Einstein SG; Thomson GT; Beaulieu A; Choquette D; Maksymowych WP
Arthritis Rheum; 2007 Dec; 56(12):4005-14. PubMed ID: 18050198
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
van der Heijde D; Pangan AL; Schiff MH; Braun J; Borofsky M; Torre J; Davis JC; Wong RL; Kupper H; Collantes E;
Ann Rheum Dis; 2008 Sep; 67(9):1218-21. PubMed ID: 18056755
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
[TBL] [Abstract][Full Text] [Related]
19. Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies.
Dubreuil M; Navarro-Compán V; Boonen A; Gaffney K; Gensler LS; de la Loge C; Vaux T; Fleurinck C; Massow U; Taieb V; Mørup MF; Deodhar A; Rudwaleit M
RMD Open; 2024 Jun; 10(2):. PubMed ID: 38834351
[TBL] [Abstract][Full Text] [Related]
20. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial.
Navarro-Compán V; Wei JC; Van den Bosch F; Magrey M; Wang L; Fleishaker D; Cappelleri JC; Wang C; Wu J; Dina O; Fallon L; Strand V
RMD Open; 2022 Jun; 8(2):. PubMed ID: 35654457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
